These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36153202)

  • 61. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
    Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
    JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Kinase fusion positive intra-osseous spindle cell tumors: A series of eight cases with review of the literature.
    Suurmeijer AJH; Xu B; Torrence D; Dickson BC; Antonescu CR
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23205. PubMed ID: 37782551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 64. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [TBL] [Abstract][Full Text] [Related]  

  • 65.
    Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
    Forschner A; Forchhammer S; Bonzheim I
    J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P; Foglizzo V; Harada G; Repetto M; Kulick A; de Stanchina E; de Marchena M; Auwardt S; Sayed Ahmed S; Bremer NV; Yang SR; Feng Y; Zhou C; Kong N; Liang R; Xu H; Zhang B; Bardelli A; Toska E; Ventura A; Drilon A; Cocco E
    Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment.
    Chen W; Wang H; Jiang D; Luan L; Zhou Y; Hou Y
    World J Surg Oncol; 2021 Apr; 19(1):136. PubMed ID: 33941195
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 73. NTRK-rearranged spindle cell sarcoma of the uterine cervix with a novel NUMA1::NTRK1 fusion.
    Szalai L; Vereczkey I; Szemes M; Rókusz A; Csernák E; Tóth E; Melegh Z
    Virchows Arch; 2024 Mar; 484(3):527-531. PubMed ID: 38151535
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.
    Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR
    Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
    Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
    Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
    [No Abstract]   [Full Text] [Related]  

  • 76. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
    Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.
    Hong DS; Drilon A; Wirth LJ
    Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
    Solomon JP; Linkov I; Rosado A; Mullaney K; Rosen EY; Frosina D; Jungbluth AA; Zehir A; Benayed R; Drilon A; Hyman DM; Ladanyi M; Sireci AN; Hechtman JF
    Mod Pathol; 2020 Jan; 33(1):38-46. PubMed ID: 31375766
    [TBL] [Abstract][Full Text] [Related]  

  • 80. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
    Rolfo C; Drilon A; Hong D; McCoach C; Dowlati A; Lin JJ; Russo A; Schram AM; Liu SV; Nieva JJ; Nguyen T; Eshaghian S; Morse M; Gettinger S; Mobayed M; Goldberg S; Araujo-Mino E; Vidula N; Bardia A; Subramanian J; Sashital D; Stinchcombe T; Kiedrowski L; Price K; Gandara DR
    Br J Cancer; 2022 Feb; 126(3):514-520. PubMed ID: 34480094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.